海思科8月22日晚间发布公告称，公司第五届第二十九次董事会会议于2025年8月22日以通讯表决方式召 开。会议审议了《2025年半年度报告及摘要》等文件。 （文章来源：每日经济新闻） ...

证券代码：002653 证券简称：海思科 公告编号：2025-094 海思科医药集团股份有限公司 2025 年半年度募集资金存放与实际使用情况 的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司募集资金监管规则》 和深圳证券交易所发布的《上市公司自律监管指引第 1 号—主板上市公 司规范运作》等有关规定，海思科医药集团股份有限公司（以下简称 "公司"）董事会编制了截至 2025 年 6 月 30 日募集资金存放与实际使 用情况的专项报告。 一、 募集资金基本情况 募集资金投资项目资金使用情况详见附表 1：募集资金使用情况对 照表。 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于核准海思科医药集团股份有限公 司非公开发行股票的批复》（证监许可〔2022〕869 号）核准，公司于 2023 年 2 月 10 日非公开发行人民币普通股（A 股）股票 40,000,000 股， 发行价格为 20.00 元/股，募集资金总额为人民币 800,000,000.00 元， 扣除各项发行费用人民币 9,133, ...

海思科医药集团股份有限公司 2025 年半年度财务报告 海思科医药集团股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 海思科医药集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：海思科医药集团股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 1,456,575,522.37 | 1,056,036,624.42 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | 150,132,639.04 | | 衍生金融资产 | | | | 应收票据 | 46,475,925.18 | 79,492,047.42 | | 应收账款 | 939,956,132.27 | 838,015,938.18 | | 应收款项融资 | 19,191,114.70 | 159,121,780.06 | | ...

证券代码：002653 证券简称：海思科 公告编号：2025-095 海思科医药集团股份有限公司 关于使用自有资金支付募投项目部分款项 并以募集资金等额置换的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第五届董事会第二十九次会议，审议通过了《关于使 用自有资金支付募投项目部分款项并以募集资金等额置换的议案》， 同意公司在募集资金投资项目（以下简称"募投项目"）实施期间， 先行使用自有资金支付募投项目部分款项，后续再定期以募集资金等 额置换，从募集资金专户划转等额至公司自有账户，该部分等额置换 资金视同募投项目使用。现将相关内容公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会《关于核准海思科医药集团股份有限 公司非公开发行股票的批复》（证监许可〔2022〕869 号）核准，公 司于 2023 年 2 月 10 日非公开发行人民币普通股（A 股）股票 40,000,000 股，发行价格为 20.00 元/股，募集资金总额为人民币 800,000,000.00 ...

附件一 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | | 2025年期初占用资金余额 | 2025年半年度往来累计发生 | 2025年半年度往来资 | 2025年半年度偿还 | 2025年半年度期末 | 占用形成原因 | | 占用性质 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | | | 金额（不含利息） | 金的利息（如有） | 累计发生金额 | 往来资金余额 | | | | | | 控股股东、实际控制人及其附属企业 | | - | - | - | - | - | | - | - | - | - | | - | | 小计 | | - | - | - | - | - | | - | - | - | - | | - | | 前控股股东、实际控制人及其附属企业 | | - | - | - | - | - | | - | - | - | - | | - | | 小计 | | - | - | - | - ...

证券代码：002653 证券简称：海思科 公告编号：2025-092 海思科医药集团股份有限公司 第五届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）第五届董事 会第二十九次会议（以下简称"会议"）于 2025 年 8 月 22 日以通讯 表决方式召开。会议通知于 2025 年 8 月 12 日以传真方式送达。会议 应出席董事 5 人，以通讯表决方式出席董事 5 人。会议由公司董事长 王俊民先生召集并主持。本次会议的通知、召开以及参与表决董事人 数均符合有关法律、法规、规则及《公司章程》的有关规定。全体董 事经过审议，以投票表决方式通过了如下决议： 一、审议通过了《2025 年半年度报告及摘要》 表决结果：5 票同意、0 票弃权、0 票反对 本议案已经公司董事会审计委员会审议通过。 详见公司同日刊登于巨潮资讯网等公司指定信息披露媒体的 《2025 年半年度报告及摘要》。 二、审议通过了《关于使用自有资金支付募投项目部分款项并以 募集资金等额置换的议案》 表决结果：5 票同意、0 票弃 ...

格隆汇8月22日丨海思科(002653.SZ)公布2025年半年度报告，上半年公司实现营业收入20.01亿元，同比 增长18.63%；归属于上市公司股东的净利润1.29亿元，同比下降21.79%；归属于上市公司股东的扣除非 经常性损益的净利润1.45亿元，同比增长90.84%；基本每股收益0.12元。 ...

中信证券股份有限公司 关于海思科医药集团股份有限公司使用自有资金支付募投项目部分 款项并以募集资金等额置换的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）为海思科 医药集团股份有限公司（以下简称"公司"、"海思科"）非公开发行股票的持 续督导机构，于 2025 年 6 月承接原保荐机构华泰联合证券有限责任公司就未使 用完毕的募集资金使用情况继续履行持续督导责任。根据《证券发行上市保荐业 务管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等有关规定，对海思科使用自 有资金支付募投项目部分款项并以募集资金等额置换事项进行了核查，并出具核 查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准海思科医药集团股份有限公司非公开 发行股票的批复》（证监许可〔2022〕869 号）核准，公司于 2023 年 2 月 10 日 非公开发行人民币普通股（A 股）股票 40,000,000 股，发行价格为 20.00 元/股， 募 集 资 金 总 额 为 人 民 币 800,000,000.00 元 ， 扣 除 各 项 ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 2,000,844,469.01, representing an increase of 18.63% compared to CNY 1,686,644,106.03 in the same period last year[17]. - Net profit attributable to shareholders decreased by 21.79% to CNY 128,821,952.97 from CNY 164,716,596.18 year-on-year[17]. - The net profit after deducting non-recurring gains and losses increased by 90.84% to CNY 144,624,555.05, compared to CNY 75,781,981.04 in the previous year[17]. - The net cash flow from operating activities surged by 216.54% to CNY 349,631,890.42, up from CNY 110,454,565.67 in the same period last year[17]. - Basic earnings per share decreased by 20.00% to CNY 0.12 from CNY 0.15 in the same period last year[17]. - The weighted average return on net assets was 3.11%, down from 3.89% in the previous year[17]. - The company reported a significant reduction in income tax expenses, down 44.65% to ¥19,125,380.59 from ¥34,552,644.27, attributed to changes in deferred tax[74]. - The company reported a decrease in fixed assets to ¥839,029,695, which is 12.00% of total assets, down from 13.16%[84]. - The company reported a decrease in inventory from ¥271,607,934.08 to ¥299,561,691.48, which is an increase of about 10.3%[188]. Research and Development - The company has established a comprehensive technology system for drug development, facilitating rapid conversion of research results into sales[39]. - The company has received multiple industry accolades, including being named one of the top 100 pharmaceutical companies in China for 2024[38]. - The company has 58 formulation projects under research, including 33 innovative drugs and 3 improved new drugs[41]. - The company has completed IND applications for four new molecular entities in the first half of 2025, all of which have been approved for clinical trials[70]. - Research and development expenses increased by 43.02% to ¥496,553,966.24, up from ¥347,181,772.82, primarily due to increased investment in R&D[74]. - The R&D team consists of over 920 members, with approximately 44% holding master's degrees or higher, and 62% in core departments like new drug chemistry and biology[66]. - The company has a complete innovative drug R&D team and aims to attract top scientific talent to enhance its research capabilities[120]. Product Development and Market Position - The company is focused on expanding its product portfolio in key therapeutic areas such as anesthesia, neurology, and endocrinology, with over 40 products currently available[27]. - The innovative drug Sishuning® achieved sales of approximately 800 million yuan in the first half of 2025, representing a year-on-year growth of about 55%[49]. - The innovative drug Beichangping® and Simining® exceeded the average number of hospitals for chronic disease products, with over 600 hospitals each in their first year of inclusion in the national medical insurance directory[51]. - The company is committed to maintaining a customer-centric approach, continuously innovating to meet the evolving needs of healthcare providers and patients[27]. - The company aims for innovative drug sales to account for 50% of total sales in the second half of 2025, with expected sales of approximately ¥1.6 billion for the innovative drug Sushuning® (propofol injection)[56]. - The innovative drug "安瑞克芬注射液" (Anrekefen Injection) received a production approval in May 2025, marking it as the first peripheral κ-opioid receptor agonist approved for postoperative pain treatment[45]. - The innovative drug "思舒宁" (Sishuning) has 17 products in clinical stages, with a new drug application (NDA) for "general anesthesia induction" accepted by the FDA in July 2025[44]. Financial Health and Investments - The company raised ¥800,000,000 through a private placement of 40,000,000 shares at ¥20.00 per share, with a net amount of ¥790,866,217.58 after expenses[93]. - The company has committed to developing a new type of pain relief medication, with a total investment of 12.4 million yuan, achieving 100% of the planned investment by the end of the reporting period[106]. - The company has allocated 21.5 million yuan for the development and repayment of new projects, with a completion rate of 100%[107]. - The company has completed the payment of most contract final payments for the new drug research and development projects, and the supplementary working capital and bank loan repayment have been implemented[109]. - The company has established a comprehensive quality system to ensure the reliability of pharmaceutical R&D results, meeting both domestic and international regulatory requirements[69]. Market and Competitive Landscape - The company faces significant industry policy risks due to ongoing healthcare reforms, which may require timely adjustments to business strategies[117]. - Market competition is intense, with numerous generic drug products and companies, necessitating continuous innovation and product improvement to maintain market share[118]. - New drug development involves high costs and risks, with potential failures at various stages, including candidate selection and clinical trials[119]. - The company emphasizes risk management in new drug development, focusing on feasibility studies and strict evaluation processes to mitigate risks[120]. Shareholder and Governance - The company plans to not distribute cash dividends or issue bonus shares for the semi-annual period[127]. - The company has established a market value management system, which has been approved by the board of directors[124]. - The company has a total of 586,449,912 shares, with 1,609,000 shares granted as stock incentives in 2021 and 2,600,000 shares planned for 2024[173]. - The total number of common shareholders at the end of the reporting period was 11,424[175]. - Major shareholder Wang Junmin holds 35.68% of shares, totaling 399,550,400 shares, with 299,662,800 shares under pledge[175]. Compliance and Regulatory Matters - The semi-annual financial report has not been audited[142]. - There have been no bankruptcy reorganization matters during the reporting period[143]. - The company reported no significant litigation or arbitration matters during the reporting period[144]. - There were no major penalties or rectifications during the reporting period[145]. - The company did not engage in any related party transactions related to daily operations during the reporting period[146].

海思科公告，2025年上半年营业收入20.01亿元，同比增长18.63%。净利润1.29亿元，同比下降 21.79%。基本每股收益0.12元/股，同比下降20.00%。 ...